Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Marquez Website

Victor E. Marquez, Ph.D.

Selected Publications

1)  Ciarapica R, Carcarino E, Adesso L, De Salvo M, Bracaglia G, Leoncini PP, Dall Agnese A, Verginelli F, Milano GM, Boldrini R, Inserra A, Stifani S, Screpanti I, Marquez VE, Valente S, Mai A, Puri PL, Locatelli F, Palacios D, Rota R.
Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
BMC Cancer. 14: 139, 2014.
[Journal]
2)  Lad N, Sharma R, Marquez VE, Mascarenhas M.
A new synthesis of sultams from amino alcohols.
Tetrahedron Letters. 54: 6307-6309, 2013.
[Journal]
3)  Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J.
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.
Leukemia. 27: 2341-50, 2013.
[Journal]
4)  Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.
Effects of substitutions at the 4" and 2 positions on the bioactivity of 4"-ethynyl-2-fluoro-2"-deoxyadenosine.
Antimicrob. Agents Chemother. 57: 6254-64, 2013.
[Journal]
5)  Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y.
Enhancer of Zeste Homolog 2 Silences miR-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin.
Gastroenterology. 2013.
[Journal]
6)  Vella S, Gnani D, Crudele A, Ceccarelli S, De Stefanis C, Gaspari S, Nobili V, Locatelli F, Marquez VE, Rota R, Alisi A.
EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in in Vitro and in Vivo NAFLD.
Int J Mol Sci. 14: 24154-68, 2013.
[Journal]
7)  Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, Marquez VE, Zhdanova IV, Weinberg J, Costello CE, Rahimi N.
Lysine methylation promotes VEGFR-2 activation and angiogenesis.
Sci Signal. 6: ra104, 2013.
[Journal]
8)  Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, Yamanaka R, Tanaka Y, Nukiwa T, Marquez VE, Ishikawa Y, Ichinose M, Aburatani H.
PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.
Sci Rep. 3: 1911, 2013.
[Journal]
9)  Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall'agnese A, Walters ZS, Verginelli F, De Sio L, Boldrini R, Inserra A, Bisogno G, Rosolen A, Alaggio R, Ferrari A, Collini P, Locatelli M, Stifani S, Screpanti I, Rutella S, Yu Q, Marquez VE, Shipley J, Valente S, Mai A, Miele L, Puri PL, Locatelli F, Palacios D, Rota R.
The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Oncogene. 2013.
[Journal]
10)  Thompson A, Marquez VE.
Current Protocols in Nucleic Acid Chemistry: Synthesis of a North-Methanocarba-Thymidine (N-MCT) Analog. In: Wiley Online Library. Volume 1.29.
Hoboken, NJ: John Wiley & Sons; 2012. p. 1-13 [Book Chapter]
Click Here to View Expanded Bibliography.

This page was last updated on 3/12/2014.